Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Non-Current Liabilities (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $318000.0 as the latest value for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 57.88% year-over-year to $318000.0; the TTM value through Sep 2025 reached $318000.0, down 57.88%, while the annual FY2024 figure was $630000.0, 32.69% down from the prior year.
  • Total Non-Current Liabilities hit $318000.0 in Q3 2025 for Viking Therapeutics, down from $410000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.5 million in Q1 2022 and bottomed at $318000.0 in Q3 2025.
  • Average Total Non-Current Liabilities over 4 years is $931266.7, with a median of $936000.0 recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities dropped 20.74% in 2023 and then crashed 57.88% in 2025.
  • Viking Therapeutics' Total Non-Current Liabilities stood at $1.3 million in 2022, then fell by 25.71% to $936000.0 in 2023, then crashed by 32.69% to $630000.0 in 2024, then tumbled by 49.52% to $318000.0 in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $318000.0, $410000.0, and $502000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.